Abiraterone acetate: A guide to its use in metastatic castration-resistant prostate cancer - Abstract

Oral abiraterone acetate (Zytiga®), a selective cytochrome P450 17A1 enzyme inhibitor, is used in combination with prednisone or prednisolone to treat patients with metastatic castration-resistant prostate cancer (CRPC) who have previously received docetaxel-containing chemotherapy.

In a clinical trial in patients with CRPC, abiraterone acetate plus prednisone significantly prolonged overall survival, the time to prostate-specific antigen progression and progression-free survival compared with placebo plus prednisone.

Written by: 
Scott LJ, Yang LP, Lyseng-Williamson KA. Are you the author? 
Adis, Auckland, New Zealand.

Reference: Drugs Aging. 2012 Mar 1;29(3):243-8. 

doi: 10.2165/11209160-000000000-00000

PubMed Abstract 
PMID: 22372727